

Amendments to the Claims

1. (Original) An epidermal growth factor receptor (EGFR)-derived peptide or mutant peptide thereof which is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

2. (Original) The peptide of Claim 1, wherein the EGFR-derived peptide consists of at least 8 consecutive amino acid residues derived from the amino acid sequence of EGFR₈₀₀₋₈₀₉, EGFR₁₂₄₋₁₃₂, EGFR₅₄₋₆₂, EGFR₄₇₉₋₄₈₈ or EGFR₁₁₃₈₋₁₁₄₇.

3. (Original) A polypeptide consisting of 8 to 50 amino acid residues, which comprises the peptide of Claim 1 or 2 and is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

4. (Currently amended) A nucleic acid molecule encoding the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3~~.

5. (Original) A vector comprising the nucleic acid molecule of Claim 4.

6. (Currently amended) A pharmaceutical composition comprising the peptide of Claim 1 or 2, ~~the polypeptide of Claim 3, or the nucleic acid molecule of Claim 4~~, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

7. (Original) The pharmaceutical composition of Claim 6, which is used as a cancer vaccine.

8. (Currently amended) An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3~~ and an HLA molecule.

9. (Currently amended) A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3.~~

10. (Currently amended) An antibody which specifically recognizes the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3.~~

11. (New) A nucleic acid molecule encoding the polypeptide of Claim 3.

12. (New) A vector comprising the nucleic acid molecule of Claim 11.

13. (New) A pharmaceutical composition comprising the peptide of Claim 3, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

14. (New) The pharmaceutical composition of Claim 13, which is used as a cancer vaccine.

15. (New) A pharmaceutical composition comprising the nucleic acid molecule of Claim 4, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

16. (New) The pharmaceutical composition of Claim 15, which is used as a cancer vaccine.

17. (New) An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the polypeptide of Claim 3 and an HLA molecule.

18. (New) A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the polypeptide of Claim 3.

19. (New) An antibody which specifically recognizes the polypeptide of Claim 3.